Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

FDA greenlights Shire’s HAE mAB Takhzyro

The antibody, baged by Shire in 2016 by the US$ 6.5bn Dyax buy out, targets the plasma protein kallikrein, which leads to type I-III HAE by...

Urovant Sciences licenses OAB gene therapy

hMaxi-K adds to the public Swiss company’s lead product candidate in OAB, vibegron, an oral, once-daily, small molecule beta-3 agonist,...

Adaptimmune raises US$100m

The company said  that it has entered into a definitive agreement with Matrix Capital Management Company, LP, New Enterprise Associates 16,...

Roche granted breakthrough status for liver cancer combo

Based on data from a Phase Ib study, Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) were given the breakthrough designation as a...

Sanofi gets the EU’s ok for caplacizumab

The life-threatening, autoimmune-based blood clotting disorder leads to  severe thrombocytopenia, microangiopathic hemolytic anemia,...

Foundation launches £30m award

The Big Beat Challenge will bring together world-leading researchers and innovators to identify and solve any of the biggest problems in heart and...

Forbion closes Life Sciences VC Fund at €360m

Forbion IV will primarily focus on investment opportunities in the EU and the UK and only secondarily on US biotechs. As in Forbion III the...